BioNTech SE
BNTXNASDAQHealthcareBiotechnology
Previous close
$116.57
+$5.68 · +5.12%
Pre-market
$116.51
−$0.06 · -0.05%
Aug 24, 4:06 AM ET
BNTX company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Hold
Wait — insufficient conviction to act
Valuation
49
Fair Value
Momentum
38
Weakening
Sentiment
66
Bullish
Risk resilience
59
Elevated Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteBioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a for prostate cancer. BNT113 is undergoing Phase 2 investigation for HPV-positive head and neck cancers. BNT114 is in Phase 1 for triple-negative breast cancer. BNT115 is also in Phase 1, targeting ovarian cancer. BNT116 is a preclinical candidate for non-small cell lung cancer. The company also pioneers personalized therapies that target neoantigens, such as Autogene cevumeran (BNT122), which is in Phase 2 for first-line melanoma and Phase 1a/1b for a range of solid tumors. Furthermore, its pipeline includes an mRNA-based intratumoral immunotherapy, SAR441000, currently in Phase 1 for solid tumors, as well as BNT141 and BNT142, also in Phase 1 for multiple solid tumors. BioNTech's portfolio extends to RiboCytokine therapies (BNT151, BNT152, and BNT153) aimed at solid tumors, and cutting-edge chimeric antigen receptor T-cell (CAR T-cell) immunotherapies like BNT211 for various solid tumors and BNT221 for other types of cancer. Immune checkpoint modulators, specifically GEN1046 and GEN1042, are also under Phase 1/2 clinical investigation for solid tumors. Beyond these, the firm is developing BNT321, an IgG1 monoclonal antibody in Phase 2 for pancreatic cancer, and BNT411, a small molecule immunomodulator candidate for solid tumors. Its broader scope encompasses preventative vaccines for illnesses like COVID-19 and Influenza, additional immunotherapies for infectious diseases, and protein replacement therapies designed for rare conditions. To advance its extensive pipeline, BioNTech has forged strategic partnerships with major pharmaceutical and biotechnology firms, including Genentech, Sanofi S.A., Genmab A/S, Pfizer Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Regeneron Pharmaceuticals, Inc. Established in 2008, BioNTech SE maintains its principal operations in Mainz, Germany.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- DE
- CEO
- Ugur Sahin
- Listed since
- Oct 10, 2019
- Employees
- 7,807
Market position
Day range
Current $116.57
52-week range
Current $116.57
- Open
- $111.13
- Previous close
- $110.89
- Volume
- 2.96M
- 2.75× average
- Average volume
- 1.08M
- Average daily volume
- Market cap
- 29.28B USD
- Beta
- 1.28
- Market reference 1
- 50-day average
- $93.2595
- +25.00% above average
- 200-day average
- $97.5838
- +19.46% above average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 12.18B EUR
- P/E (TTM)
- -14.83×
- P/B (TTM)
- 1.43×
- P/S (TTM)
- 9.51×
- EV / EBITDA
- -19.39×
- Earnings yield
- -5.57%
- Free cash flow yield
- 1.38%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 68.95%
- Operating margin
- -64.63%
- Net margin
- -64.25%
- Return on equity
- -5.68%
- Return on assets
- -4.96%
- Return on invested capital
- -3.14%
Financial health
- Debt / equity
- 0.02×
- Current ratio
- 7.54×
- Altman Z-score
- 7.62
- Piotroski F-score
- 2 of 9
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (EUR) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 2.76B EUR | 2.75B EUR | 3.82B EUR | 17.31B EUR | 18.98B EUR |
| Cost of goods sold | 616.47M EUR | 541.3M EUR | 599.8M EUR | 3B EUR | 2.91B EUR |
| Gross profit | 2.14B EUR | 2.21B EUR | 3.22B EUR | 14.32B EUR | 16.07B EUR |
| Research and development | 2.02B EUR | 2.25B EUR | 1.78B EUR | 1.54B EUR | 949.2M EUR |
| Selling, general, and administrative | 698.2M EUR | 599M EUR | 557.7M EUR | 541.2M EUR | 327.2M EUR |
| Operating expenses | 2.76B EUR | 3.52B EUR | 2.53B EUR | 1.67B EUR | 781.4M EUR |
| Interest income | 252.24M EUR | — | 351.31M EUR | 47.37M EUR | 1.56M EUR |
| Interest expense | 13.64M EUR | 13.16M EUR | 7.76M EUR | 15.82M EUR | 5.63M EUR |
| Depreciation and amortization | 367.69M EUR | 298M EUR | 183.4M EUR | 123.3M EUR | 75.2M EUR |
| Operating income | −623.87M EUR | −1.31B EUR | 690.4M EUR | 12.64B EUR | 15.28B EUR |
| Net income | −1.09B EUR | −665.3M EUR | 930.3M EUR | 9.43B EUR | 10.29B EUR |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 55%
- 6 beats, 5 misses, 0 met estimates
- Average EPS surprise
- -23.02%
- 11 comparable reports
- Latest EPS result
- -3.7
- Estimate -2.4 · Miss by 54.29%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Analyst price target
Average target
$130.43
11.89% upsideRating distribution
24 ratingsRecent analyst actions
BNTX news
Corporate actions
Corporate action history
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Jun 2, 2022 | $2.111Irregular | Jun 3, 2022 | Jun 17, 2022 |
Ex-dividend Jun 2, 2022
$2.111
Irregular
Record Jun 3, 2022 · Payment Jun 17, 2022
BNTX peers
ETFs holding BNTX
Funds reporting this stock among their holdings, ordered by reported position size.
First Trust NYSE Arca Biotechnology Index FundFBT109.23M3.75%2.94B USD0.55%$271.07+1.10%
iShares Biotechnology ETFIBB75.82M0.72%10.75B USD0.44%$213.56+1.29%
Schwab Fundamental International Large Company Index ETFFNDF30.98M0.12%26.15B USD0.25%$55.84+0.83%
State Street SPDR Portfolio Developed World ex-US ETFSPDW10.79M0.03%41.92B USD0.03%$52.02+0.79%
VanEck Biotech ETFBBH9.29M1.98%476.57M USD0.35%$241.23+1.74%
iShares Genomics Immunology and Healthcare ETFIDNA9.23M3.75%250.38M USD0.47%$40.08+2.01%
JPMorgan BetaBuilders Europe ETFBBEU8.51M0.09%9.57B USD0.09%$80.95+0.73%
Invesco NASDAQ Next Gen 100 ETFQQQJ7.48M0.63%1.2B USD0.15%$45.9955+0.91%First Trust NYSE Arca Biotechnology Index FundFBT- Market value
- 109.23M
- Weight
- 3.75%
- AUM
- 2.94B USD
- Expense ratio
- 0.55%
- Price / 1D
- $271.07+1.10%
iShares Biotechnology ETFIBB- Market value
- 75.82M
- Weight
- 0.72%
- AUM
- 10.75B USD
- Expense ratio
- 0.44%
- Price / 1D
- $213.56+1.29%
Schwab Fundamental International Large Company Index ETFFNDF- Market value
- 30.98M
- Weight
- 0.12%
- AUM
- 26.15B USD
- Expense ratio
- 0.25%
- Price / 1D
- $55.84+0.83%
State Street SPDR Portfolio Developed World ex-US ETFSPDW- Market value
- 10.79M
- Weight
- 0.03%
- AUM
- 41.92B USD
- Expense ratio
- 0.03%
- Price / 1D
- $52.02+0.79%
VanEck Biotech ETFBBH- Market value
- 9.29M
- Weight
- 1.98%
- AUM
- 476.57M USD
- Expense ratio
- 0.35%
- Price / 1D
- $241.23+1.74%
iShares Genomics Immunology and Healthcare ETFIDNA- Market value
- 9.23M
- Weight
- 3.75%
- AUM
- 250.38M USD
- Expense ratio
- 0.47%
- Price / 1D
- $40.08+2.01%
JPMorgan BetaBuilders Europe ETFBBEU- Market value
- 8.51M
- Weight
- 0.09%
- AUM
- 9.57B USD
- Expense ratio
- 0.09%
- Price / 1D
- $80.95+0.73%
Invesco NASDAQ Next Gen 100 ETFQQQJ- Market value
- 7.48M
- Weight
- 0.63%
- AUM
- 1.2B USD
- Expense ratio
- 0.15%
- Price / 1D
- $45.9955+0.91%
Continue in GoAI
Research BNTXresearch.disclaimer